Editing Filgrastim (section)

==Medical uses==
Filgrastim is used to treat neutropenia;<ref name="Neupogen FDA label" /> acute myeloid leukemia;<ref name="Neupogen FDA label" /> nonmyeloid malignancies;<ref name="Neupogen FDA label" /> leukapheresis;<ref name="Neupogen FDA label" /> congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia;<ref name="Neupogen FDA label" /> and myelosuppressive doses of radiation.<ref name="Neupogen FDA label" /><ref>{{cite web | title=FDA Approves Radiation Medical Countermeasure | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 March 2015 | url=https://www.fda.gov/emergency-preparedness-and-response/about-mcmi/fda-approves-radiation-medical-countermeasure | archive-url=https://web.archive.org/web/20190930183616/https://www.fda.gov/emergency-preparedness-and-response/about-mcmi/fda-approves-radiation-medical-countermeasure | url-status=dead | archive-date=30 September 2019 | access-date=8 September 2023}}</ref>

Tbo-filgrastim (Granix) is [[indicated]] for reduction in the duration of severe neutropenia in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.<ref name="Granix FDA label">{{cite web | title=Granix- tbo-filgrastim injection, solution | website=DailyMed | date=30 November 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df918ec2-0907-443f-a52a-b72866959644 | access-date=8 September 2023}}</ref>